Cargando…

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen

Kidney fibrosis is the final common pathway of progressive kidney diseases including diabetic nephropathy. Here, we report that the endogenous antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), the substrate of angiotensin-converting enzyme (ACE), is an orally available peptide dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nitta, Kyoko, Shi, Sen, Nagai, Takako, Kanasaki, Megumi, Kitada, Munehiro, Srivastava, Swayam Prakash, Haneda, Masakazu, Kanasaki, Keizo, Koya, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818806/ https://www.ncbi.nlm.nih.gov/pubmed/27088094 http://dx.doi.org/10.1155/2016/9172157

Ejemplares similares

N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
por: Kanasaki, Keizo, et al.
Publicado: (2014)

N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014)

Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2016)

Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
por: Kanasaki, Megumi, et al.
Publicado: (2011)

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway
por: Li, Jinpeng, et al.
Publicado: (2017)

βklotho is essential for the anti‐endothelial mesenchymal transition effects of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline
por: Gao, Rongfen, et al.
Publicado: (2019)

N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects
por: Kanasaki, Keizo
Publicado: (2020)

N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice
por: Chan, Gary C. W., et al.
Publicado: (2015)

N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling
por: Shi, Yingying, et al.
Publicado: (2020)

Acetylated α-Tubulin Regulated by N-Acetyl-Seryl-Aspartyl-Lysyl-Proline(Ac-SDKP) Exerts the Anti-fibrotic Effect in Rat Lung Fibrosis Induced by Silica
por: Xiaojun, Wang, et al.
Publicado: (2016)

Dietary Restriction Ameliorates Diabetic Nephropathy through Anti-Inflammatory Effects and Regulation of the Autophagy via Restoration of Sirt1 in Diabetic Wistar Fatty (fa/fa) Rats: A Model of Type 2 Diabetes
por: Kitada, Munehiro, et al.
Publicado: (2011)

Restoration of the Hypothalamic-pituitary-adrenal Response to Hypoglycemia in Type 2 Diabetes by Avoiding Chronic Hypoglycemia
por: Tsuda, Shin-ichi, et al.
Publicado: (2016)

The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis
por: Mnguni, Ayanda Trevor, et al.
Publicado: (2015)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Effects of N‐acetyl‐seryl‐asparyl‐lysyl‐proline on blood pressure, renal damage, and mortality in systemic lupus erythematosus
por: Nakagawa, Pablo, et al.
Publicado: (2017)

Diabetic angiopathy and angiogenic defects
por: Xu, Ling, et al.
Publicado: (2012)

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet
por: Takagi, Susumu, et al.
Publicado: (2018)

Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice
por: Kanasaki, Megumi, et al.
Publicado: (2017)

Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity
por: Kitada, Munehiro, et al.
Publicado: (2018)

SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2018)

Sirtuins and renal diseases: relationship with aging and diabetic nephropathy
por: Kitada, Munehiro, et al.
Publicado: (2012)

MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT
por: Srivastava, Swayam Prakash, et al.
Publicado: (2013)

CD‐1(db/db) mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis
por: Mizunuma, Yuiko, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice
por: Takagaki, Yuta, et al.
Publicado: (2019)

Renal mitochondrial oxidative stress is enhanced by the reduction of Sirt3 activity, in Zucker diabetic fatty rats
por: Ogura, Yoshio, et al.
Publicado: (2018)

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
por: Kitada, Munehiro, et al.
Publicado: (2017)

Lipid mediators in diabetic nephropathy
por: Srivastava, Swayam Prakash, et al.
Publicado: (2014)

Autophagy as a Therapeutic Target in Diabetic Nephropathy
por: Tanaka, Yuki, et al.
Publicado: (2012)

Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
por: Li, Shaolan, et al.
Publicado: (2020)

Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium–glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin‐overloaded streptozotocin‐induced diabetic mice
por: Shimada, Keiji, et al.
Publicado: (2022)

Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
por: Srivastava, Swayam Prakash, et al.
Publicado: (2020)

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
por: Kawakita, Emi, et al.
Publicado: (2021)

Editorial: Receptor Biology and Cell Signaling in Diabetes
por: Srivastava, Swayam Prakash, et al.
Publicado: (2022)

Editorial: Receptor biology and cell signaling in diabetes: volume II
por: Srivastava, Swayam Prakash, et al.
Publicado: (2023)

Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
por: Kanasaki, Keizo, et al.
Publicado: (2013)

Biology of Obesity: Lessons from Animal Models of Obesity
por: Kanasaki, Keizo, et al.
Publicado: (2011)

Loss of Mitochondrial Control Impacts Renal Health
por: Srivastava, Swayam Prakash, et al.
Publicado: (2020)

Editorial: Combating Diabetes and Diabetic Kidney Disease
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9equnlvb7gvp4hdho1rr5c1mk9